Oliver Engel1, Armin Soave1, Sven Peine2, Luis A Kluth1, Marianne Schmid1, Shahrokh F Shariat3, Roland Dahlem1, Margit Fisch1, Michael Rink4. 1. Department of Urology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany. 2. Institute of Transfusion Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 3. Department of Urology, University Medical Center Vienna, Vienna, Austria. 4. Department of Urology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany. mrink@uke.uni-hamburg.de.
Abstract
PURPOSE: To investigate the impact of the AB0 and the Rhesus blood group system on outcomes of urothelial carcinoma of the bladder (UCB) patients treated with radical cystectomy (RC). METHODS: We included 511 UCB patients treated with RC without neoadjuvant chemotherapy from 1996 to 2011 at our institution. Cox and logistic regression models assessed the association of the AB0 blood group antigen and Rhesus factor expression with tumor biologic features and outcomes, respectively. RESULTS: In total, 216 patients (42.3 %) had the blood group antigen A0, 73 patients (14.3 %) the antigen B0, 33 patients (6.4 %) the antigen AB and 189 patients (37.0 %) the antigen 00. In addition, 414 patients (81.0 %) were Rhesus factor positive. The AB0 blood group antigen expression was associated with a higher tumor grade (p = 0.003). In contrast, the Rhesus factor was not associated with any clinicopathologic characteristics. Neither the AB0 blood group antigens nor the Rhesus factor was associated with survival. In a sensitivity analysis of patients receiving adjuvant chemotherapy, however, the blood group antigen AB expression was associated with reduced cancer-specific and overall survival. CONCLUSION: The AB0 blood group antigens and the Rhesus factor are not associated with survival. Although the AB0 blood groups and the Rhesus factor are analyzed in every patient treated with RC, they do not represent appropriate biomarkers for UCB outcome prognostication. The association of the AB0 blood group antigens with response to adjuvant chemotherapy requires further validation.
PURPOSE: To investigate the impact of the AB0 and the Rhesus blood group system on outcomes of urothelial carcinoma of the bladder (UCB) patients treated with radical cystectomy (RC). METHODS: We included 511 UCB patients treated with RC without neoadjuvant chemotherapy from 1996 to 2011 at our institution. Cox and logistic regression models assessed the association of the AB0 blood group antigen and Rhesus factor expression with tumor biologic features and outcomes, respectively. RESULTS: In total, 216 patients (42.3 %) had the blood group antigen A0, 73 patients (14.3 %) the antigen B0, 33 patients (6.4 %) the antigen AB and 189 patients (37.0 %) the antigen 00. In addition, 414 patients (81.0 %) were Rhesus factor positive. The AB0 blood group antigen expression was associated with a higher tumor grade (p = 0.003). In contrast, the Rhesus factor was not associated with any clinicopathologic characteristics. Neither the AB0 blood group antigens nor the Rhesus factor was associated with survival. In a sensitivity analysis of patients receiving adjuvant chemotherapy, however, the blood group antigen AB expression was associated with reduced cancer-specific and overall survival. CONCLUSION: The AB0 blood group antigens and the Rhesus factor are not associated with survival. Although the AB0 blood groups and the Rhesus factor are analyzed in every patient treated with RC, they do not represent appropriate biomarkers for UCB outcome prognostication. The association of the AB0 blood group antigens with response to adjuvant chemotherapy requires further validation.
Entities:
Keywords:
AB0 blood group system; Outcome; Radical cystectomy; Rhesus blood group system; Urinary bladder cancer; Urothelial carcinoma
Authors: Michael Rink; Eugene K Cha; David Green; Jens Hansen; Brian D Robinson; Yair Lotan; Arthur I Sagalowsky; Felix K Chun; Pierre I Karakiewicz; Margit Fisch; Douglas S Scherr; Shahrokh F Shariat Journal: Curr Urol Rep Date: 2012-04 Impact factor: 3.092
Authors: Tobias Klatte; Evanguelos Xylinas; Malte Rieken; Morgan Rouprêt; Harun Fajkovic; Christian Seitz; Pierre I Karakiewicz; Yair Lotan; Marko Babjuk; Michela de Martino; Shahrokh F Shariat Journal: Urol Oncol Date: 2014-02-02 Impact factor: 3.498
Authors: Giacomo Novara; Robert S Svatek; Pierre I Karakiewicz; Eila Skinner; Vincenzo Ficarra; Yves Fradet; Yair Lotan; Hendrik Isbarn; Umberto Capitanio; Patrick J Bastian; Wassim Kassouf; Hans-Martin Fritsche; Jonathan I Izawa; Derya Tilki; Colin P Dinney; Seth P Lerner; Mark Schoenberg; Bjoern G Volkmer; Arthur I Sagalowsky; Shahrokh F Shariat Journal: J Urol Date: 2010-06 Impact factor: 7.450
Authors: A Soave; R Dahlem; J Hansen; L Weisbach; S Minner; O Engel; L A Kluth; F K Chun; S F Shariat; M Fisch; M Rink Journal: Eur J Surg Oncol Date: 2014-03-13 Impact factor: 4.424
Authors: Michael Rink; Daniel J Lee; Matthew Kent; Evanguelos Xylinas; Hans-Martin Fritsche; Marko Babjuk; Antonin Brisuda; Jens Hansen; David A Green; Atiqullah Aziz; Eugene K Cha; Giacomo Novara; Felix K Chun; Yair Lotan; Patrick J Bastian; Derya Tilki; Paolo Gontero; Armin Pycha; Jack Baniel; Roy Mano; Vincenzo Ficarra; Quoc-Dien Trinh; Scott T Tagawa; Pierre I Karakiewicz; Douglas S Scherr; Daniel D Sjoberg; Shahrokh F Shariat Journal: BJU Int Date: 2012-09-03 Impact factor: 5.588
Authors: Simona Iodice; Patrick Maisonneuve; Edoardo Botteri; Maria Teresa Sandri; Albert B Lowenfels Journal: Eur J Cancer Date: 2010-12 Impact factor: 9.162
Authors: J Alfred Witjes; Eva Compérat; Nigel C Cowan; Maria De Santis; Georgios Gakis; Thierry Lebret; Maria J Ribal; Antoine G Van der Heijden; Amir Sherif Journal: Eur Urol Date: 2013-12-12 Impact factor: 20.096
Authors: Andrea Mari; Riccardo Campi; Riccardo Tellini; Giorgio Gandaglia; Simone Albisinni; Mohammad Abufaraj; Georgios Hatzichristodoulou; Francesco Montorsi; Roland van Velthoven; Marco Carini; Andrea Minervini; Shahrokh F Shariat Journal: World J Urol Date: 2017-11-16 Impact factor: 4.226
Authors: Veronika Seebacher; Stephan Polterauer; Alexander Reinthaller; Heinz Koelbl; Regina Achleitner; Astrid Berger; Nicole Concin Journal: BMC Cancer Date: 2018-04-19 Impact factor: 4.430